A surge of innovation in next-generation drugs for diabetes treatment is reshaping therapeutic strategies by targeting novel metabolic pathways. Beyond conventional insulin and oral hypoglycemics, recent developments include dual and triple agonists that simultaneously modulate multiple hormonal pathways, such as GLP-1/GIP receptor agonists. Sodium-glucose co-transporter inhibitors (SGLT1/SGLT2) continue to gain traction due to their cardiovascular and renal protective effects. Additionally, small-molecule insulin mimetics and gene-editing techniques are opening new avenues for disease-modifying treatments. Personalized medicine approaches and advancements in drug delivery systems, including smart insulin and implantable devices, are enhancing efficacy while minimizing side effects. These breakthroughs offer promising prospects for achieving sustained glycemic control and preventing diabetes-related complications.
Submit your abstract Today
